{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:59:40Z","timestamp":1769601580358,"version":"3.49.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1097\/cji.0b013e31818b3dad","type":"journal-article","created":{"date-parts":[[2008,12,18]],"date-time":"2008-12-18T08:39:47Z","timestamp":1229589587000},"page":"54-65","source":"Crossref","is-referenced-by-count":50,"title":["The Immune Adjuvant Properties of Front-line Carboplatin-Paclitaxel: A Randomized Phase 2 Study of Alternative Schedules of Intravenous Oregovomab Chemoimmunotherapy in Advanced Ovarian Cancer"],"prefix":"10.1097","volume":"32","author":[{"given":"Patricia","family":"Braly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher F.","family":"Nicodemus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Schoonmaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Whiteside","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley Mary","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Method","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210208","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"R3-7-20210208","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1200\/JCO.2003.03.039","article-title":"Maintenance therapy in advanced ovarian cancer: Progression-free survival and clinical benefit","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"R4-7-20210208","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/10849780152389384","article-title":"Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13\u2013evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo","volume":"16","author":"Noujaim","year":"2001","journal-title":"Cancer Biother Radiopharm"},{"key":"R5-7-20210208","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ygyno.2004.04.024","article-title":"CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients","volume":"94","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R6-7-20210208","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1517\/14712598.7.3.331","article-title":"Role of monoclonal antibodies in tumor-specific immunity","volume":"7","author":"Nicodemus","year":"2007","journal-title":"Exp Opin Biol Ther"},{"key":"R7-7-20210208","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.2004.09.016","article-title":"Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer","volume":"22","author":"Berek","year":"2004","journal-title":"J Clin Oncol"},{"key":"R9-7-20210208","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"R10-7-20210208","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.2004.06.043","article-title":"Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine","volume":"22","author":"Berd","year":"2004","journal-title":"J Clin Oncol"},{"key":"R11-7-20210208","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/0008-5472.CAN-05-1797","article-title":"Leveraging the activity of tumor vaccines with Cytotoxic chemotherapy","volume":"65","author":"Emens","year":"2005","journal-title":"Cancer Res"},{"key":"R12-7-20210208","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/jnci\/dji027","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"97","author":"Taylor","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R13-7-20210208","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002620050479","article-title":"Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)","volume":"46","author":"Schultes","year":"1998","journal-title":"Cancer Immunol Immunother"},{"key":"R14-7-20210208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(03)00253-9","article-title":"Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay","volume":"279","author":"Schultes","year":"2003","journal-title":"J Immunol Methods"},{"key":"R15-7-20210208","first-page":"271","article-title":"Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses","volume":"24","author":"Tanir","year":"2003","journal-title":"Eur J Gynaecol Oncol"},{"key":"R16-7-20210208","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/humrep\/deg321","article-title":"Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours","volume":"18","author":"Darai","year":"2003","journal-title":"Hum Reprod"},{"key":"R17-7-20210208","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1006\/gyno.1998.4974","article-title":"High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer","volume":"69","author":"Maccio","year":"1998","journal-title":"Gynecol Oncol"},{"key":"R19-7-20210208","first-page":"734","article-title":"Chemotherapy Augments TRAIL-induced Apoptosis in Breast Cell Lines","volume":"59","author":"Keane","year":"1999","journal-title":"Cancer Res"},{"key":"R20-7-20210208","first-page":"3689","article-title":"Cyclophosphamide, Doxorubicin, and Paclitaxel enhance the antitumor immune response of granulocyte\/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2\/neu tolerized mice","volume":"61","author":"Machiels","year":"2001","journal-title":"Cancer Res"},{"key":"R21-7-20210208","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1046\/j.1365-2141.2002.03645.x","article-title":"MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells","volume":"118","author":"Wang","year":"2002","journal-title":"Br J Haematol"},{"key":"R22-7-20210208","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J Immunol"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CJI.0b013e31818b3dad","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T01:17:56Z","timestamp":1684804676000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002371-200901000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e31818b3dad","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}